Cognition Therapeutics rises as it extends access to rare brain disorder drug

Shares of drug developer Cognition Therapeutics CGTX.O rise 1.9% to $1.05 premarket

Co says it extended its access program for zervimesine, an experimental drug for Lewy body dementia - a disorder that affects movement, thinking and behavior

Co says the program now allows patients to stay on the daily 100 mg oral drug for several more months beyond the original one‑year plan

Program began in June 2025 and has enrolled 32 patients across eight U.S. sites

Co recently finished a mid‑stage study in Lewy body dementia and discussed results with the FDA; meeting minutes expected this month - CGTX

CGTX's zervimesine is also being studied in Alzheimer’s and age‑related macular degeneration, says co

Shares up ~93% in 2025